Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum-Reference-Cited by-同舟云学术

Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum

Published:2012-02-16 Issue:6 Volume:106 Page:1039-1044
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Yoon D H,Ryu M-H,Park Y S,Lee H J,Lee C,Ryoo B-Y,Lee J-L,Chang H-M,Kim T W,Kang Y-K

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc201247.pdf

Reference16 articles.

1. Bjornsti MA, Houghton PJ ( 2004 ) The TOR pathway: a target for cancer therapy . Nat Rev Cancer 4 (5) : 335 – 348

2. Castellvi J, Garcia A, Rojo F, Ruiz-Marcellan C, Gil A, Baselga J, Ramon y Cajal S ( 2006 ) Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer . Cancer 107 (8) : 1801 – 1811

3. Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M, Youmans A, Polivy A, Mandato L, McDermott D, Stanbridge E, Atkins M ( 2007 ) Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma . Clin Genitourin Cancer 5 (6) : 379 – 385

4. Ciuffreda L, Di Sanza C, Incani UC, Milella M ( 2010 ) The mTOR pathway: a new target in cancer therapy . Curr Cancer Drug Targets 10 (5) : 484 – 495

5. Crouthamel MC, Kahana JA, Korenchuk S, Zhang SY, Sundaresan G, Eberwein DJ, Brown KK, Kumar R ( 2009 ) Mechanism and management of AKT inhibitor-induced hyperglycemia . Clin Cancer Res 15 (1) : 217 – 225

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling promising targets in gastric cancer therapy: A comprehensive review;Molecular Therapy: Oncology;2024-09

2. p70S6K/Akt dual inhibitor DIACC3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumab;Scientific Reports;2023-09-25

3. Unique Genomic Alterations and Microbial Profiles Identified in Patients With Gastric Cancer of African, European, and Asian Ancestry;Annals of Surgery;2023-06-29

4. Synergistic anticancer effects of everolimus (RAD001) and Rhein on gastric cancer cells via phosphoinositide-3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway;Bioengineered;2022-02-28

5. Development of Novel Cancer Biomarkers for Diagnosis and Prognosis;Cancer Biomarkers in Diagnosis and Therapeutics;2022